In silico selection of therapeutic antibodies for development: viscosity, clearance, and chemical stability
VK Sharma, TW Patapoff, B Kabakoff… - Proceedings of the …, 2014 - National Acad Sciences
For mAbs to be viable therapeutics, they must be formulated to have low viscosity, be
chemically stable, and have normal in vivo clearance rates. We explored these properties by …
chemically stable, and have normal in vivo clearance rates. We explored these properties by …
[HTML][HTML] In silico selection of therapeutic antibodies for development: Viscosity, clearance, and chemical stability
VK Sharma, TW Patapoff, B Kabakoff, S Pai… - Proceedings of the …, 2014 - ncbi.nlm.nih.gov
For mAbs to be viable therapeutics, they must be formulated to have low viscosity, be
chemically stable, and have normal in vivo clearance rates. We explored these properties by …
chemically stable, and have normal in vivo clearance rates. We explored these properties by …
[PDF][PDF] In silico selection of therapeutic antibodies for development: Viscosity, clearance, and chemical stability
VK Sharmaa, TW Patapoffa, B Kabakoffa, S Paia… - PNAS, 2014 - academia.edu
For mAbs to be viable therapeutics, they must be formulated to have low viscosity, be
chemically stable, and have normal in vivo clearance rates. We explored these properties by …
chemically stable, and have normal in vivo clearance rates. We explored these properties by …
In silico selection of therapeutic antibodies for development: Viscosity, clearance, and chemical stability
VK Sharma, TW Patapoff, B Kabakoff, S Pai… - Proceedings of the …, 2014 - cir.nii.ac.jp
抄録< jats: title> Significance</jats: title>< jats: p> mAbs are increasingly being used for
treatment of chronic diseases wherein the subcutaneous delivery route is preferred to …
treatment of chronic diseases wherein the subcutaneous delivery route is preferred to …
In silico selection of therapeutic antibodies for development: Viscosity, clearance, and chemical stability
VK Sharma, TW Patapoff, B Kabakoff… - Proceedings of the …, 2014 - ui.adsabs.harvard.edu
Abstract mAbs are increasingly being used for treatment of chronic diseases wherein the
subcutaneous delivery route is preferred to enable self-administration and at-home use. To …
subcutaneous delivery route is preferred to enable self-administration and at-home use. To …
In silico selection of therapeutic antibodies for development: Viscosity, clearance, and chemical stability
VK Sharma, TW Patapoff, B Kabakoff… - Proceedings of the …, 2014 - escholarship.org
For mAbs to be viable therapeutics, they must be formulated to have low viscosity, be
chemically stable, and have normal in vivo clearance rates. We explored these properties by …
chemically stable, and have normal in vivo clearance rates. We explored these properties by …
In silico selection of therapeutic antibodies for development: viscosity, clearance, and chemical stability.
VK Sharma, TW Patapoff, B Kabakoff, S Pai… - Proceedings of the …, 2014 - europepmc.org
For mAbs to be viable therapeutics, they must be formulated to have low viscosity, be
chemically stable, and have normal in vivo clearance rates. We explored these properties by …
chemically stable, and have normal in vivo clearance rates. We explored these properties by …
[PDF][PDF] In silico selection of therapeutic antibodies for development: Viscosity, clearance, and chemical stability
VK Sharmaa, TW Patapoffa, B Kabakoffa, S Paia… - PNAS, 2014 - researchgate.net
For mAbs to be viable therapeutics, they must be formulated to have low viscosity, be
chemically stable, and have normal in vivo clearance rates. We explored these properties by …
chemically stable, and have normal in vivo clearance rates. We explored these properties by …
In silico selection of therapeutic antibodies for development: viscosity, clearance, and chemical stability
VK Sharma, TW Patapoff, B Kabakoff… - Proceedings of the …, 2014 - pubmed.ncbi.nlm.nih.gov
For mAbs to be viable therapeutics, they must be formulated to have low viscosity, be
chemically stable, and have normal in vivo clearance rates. We explored these properties by …
chemically stable, and have normal in vivo clearance rates. We explored these properties by …
In silico selection of therapeutic antibodies for development: viscosity, clearance, and chemical stability.
VK Sharma, TW Patapoff, B Kabakoff, S Pai… - Proceedings of the …, 2014 - europepmc.org
For mAbs to be viable therapeutics, they must be formulated to have low viscosity, be
chemically stable, and have normal in vivo clearance rates. We explored these properties by …
chemically stable, and have normal in vivo clearance rates. We explored these properties by …